Head and neck melanoma: the eyelid region has a better prognosis and easier management: a retrospective survey and systematic review.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
4
6
2024
Statut:
aheadofprint
Résumé
Eyelid melanoma (EM) is a malignant neoplasm accounting for around 1% of eyelid malignancies. Because of its rarity, most of our knowledge of EM is currently based on studies of cutaneous melanomas located elsewhere. Accordingly, this study aimed to specifically evaluate EM characteristics, management strategies, and prognosis. A retrospective study was carried out on patients diagnosed with EM at Careggi University Hospital, Florence between May 2012 and May 2022. In addition, a systematic review of relevant literature was conducted, encompassing studies published from 2013 to 2023. Clinical, histopathological, therapeutical, and prognostic data were analyzed to assess the metastasis rate and the 5-year survival rate of patients with EM. Separate data were extracted for in situ and invasive disease. Our original study included 19 patients diagnosed with EM with a 5-year survival rate of 100% for in situ and 83.3% for invasive EM. The literature review identified five poorly detailed large database reviews and 14 original studies on EM with an overall 5-year survival rate of 79.7%. The present research indicates that EM is a challenging malignancy, but has a relatively better prognosis and easier management than other melanomas of the head and neck region. These are probably related to the anatomical location which leads to early diagnosis. Therefore, EM should be considered as a specific disease requiring dedicated treatment. Based on the personal authors' experience and comprehensive overview of the current knowledge, a dedicated protocol is proposed.
Identifiants
pubmed: 38833343
doi: 10.1097/CMR.0000000000000984
pii: 00008390-990000000-00152
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Cook BE Jr., Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology 1999; 106:746–750.
Zoltie N, O’Neill TJ. Malignant melanomas of eyelid skin. Plast Reconstr Surg 1989; 83:994–996.
Go CC, Kim DH, Go BC, McGeehan B, Briceño CA. Clinicopathologic characteristics and prognostic factors impacting survival in melanoma of the eyelid. Am J Ophthalmol 2022; 234:71–80.
Shan Y, Xu Y, Lu Y, Chen M, Cao J, Wang Y, et al. Epidemiology and survival outcomes for eyelid primary malignant melanoma: an analysis of 1397 cases in the SEER Database. J Ophthalmol 2020; 2020:4858636.
Downing A, Newton-Bishop JA, Forman D. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. Br J Cancer 2006; 95:91–95.
de Giorgi V, Rossari S, Gori A, Grazzini M, Savarese I, Crocetti E, et al. The prognostic impact of the anatomical sites in the ‘head and neck melanoma’: scalp versus face and neck. Melanoma Res 2012; 22:402–405.
Lin D, Franc BL, Kashani-Sabet M, Singer MI. Lymphatic drainage patterns of head and neck cutaneous melanoma observed on lymphoscintigraphy and sentinel lymph node biopsy. Head Neck 2006; 28:249–255.
Dini F, Susini P, Nisi G, Cuomo R, Grimaldi L, Massi D, et al. Periocular sebaceous carcinoma: updates in the diagnosis, treatment, staging, and management. Int J Dermatol 2024; 63:726–736.
National Comprehensive Cancer Network (NCCN). Practice guidelines in oncology: melanoma; 2009. www.nccn.org. [Accessed 20 October 2023]
Cook J, Zitelli JA. Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol 1998; 39:698–703.
Otley CC, Salasche SJ. Mohs surgery: efficient and effective. Br J Ophthalmol 2004; 88:1228.
Mancera N, Smalley KSM, Margo CE. Melanoma of the eyelid and periocular skin: histopathologic classification and molecular pathology. Surv Ophthalmol 2019; 64:272–288.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al.; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics – update 2019. Eur J Cancer 2020; 126:141–158.
Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol 2008; 144:515–521.
Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol 2006; 155:771–777.
Wanebo HJ, Cooper PH, Young DV, Harpole DH, Kaiser DL. Prognostic factors in head and neck melanoma. Effect of lesion location. Cancer 1988; 62:831–837.
Golger A, Young DS, Ghazarian D, Neligan PC. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. Arch Otolaryngol Head Neck Surg 2007; 133:442–447.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41:45–60.
AIOM. Linee guida melanoma; 2021. https://www.aiom.it/linee-guida-aiom-2021-melanoma/. [Accessed 28 July 2023]
Harish V, Bond JS, Scolyer RA, Haydu LE, Saw RPM, Quinn MJ, et al. Margins of excision and prognostic factors for cutaneous eyelid melanomas. J Plast Reconstr Aesthet Surg 2013; 66:1066–1073.
Allen RC. Surgical management of periocular cancers: high- and low-risk features drive treatment. Curr Oncol Rep 2017; 19:57.
Tio D, Prinsen CAC, Dréno B, Hoekzema R, Augustin M, van Montfrans C. Variation in the diagnosis and clinical management of lentigo maligna across Europe: a survey study among European Association of Dermatologists and Venereologists members. J Eur Acad Dermatol Venereol 2018; 32:1476–1484.
Tio D, van der Woude J, Prinsen CAC, Jansma EP, Hoekzema R, van Montfrans C. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol 2017; 31:616–624.
Tas F, Erturk K. Major histotypes in skin melanoma: nodular and acral lentiginous melanomas are poor prognostic factors for relapse and survival. Am J Dermatopathol 2022; 44:799–805.
Haenssle HA, Hoffmann S, Buhl T, Emmert S, Schön MP, Bertsch HP, et al. Assessment of melanoma histotypes and associated patient related factors: basis for a predictive statistical model. J Dtsch Dermatol Ges 2015; 13:37–45.
Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17:6958–6962.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–723.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23–34.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345–1356.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381:1535–1546.
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386:444–451.
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017; 28:1631–1639.
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30–39.
Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371:1867–1876.
Namin AW, Welby L, Baker AT, Dooley LM. Positive margins in cutaneous melanoma of the head and neck: implications for timing of reconstruction. Otolaryngol Head Neck Surg 2021; 164:1052–1057.
Behbahani S, Malerba S, Maniar A, Taback B, Troob SH, Marr BP, et al. Outcomes and predictors of survival in cutaneous melanoma of the eyelid: An analysis of the National Cancer Database. J Am Acad Dermatol 2021; 84:1753–1758.
Oliver JD, Boczar D, Sisti A, Huayllani MT, Restrepo DJ, Spaulding AC, et al. Eyelid melanoma in the United States: a National Cancer Database analysis. J Craniofac Surg 2019; 30:2412–2415.
Bladen JC, Malhotra R, Litwin A. Long-term outcomes of margin-controlled excision for eyelid melanoma. Eye (Lond) 2023; 37:1009–1013.
Shi K, Wang L, Srivastava D, Nijhawan RI. Mohs micrographic surgery for periocular skin cancer: a single-institution experience. Arch Dermatol Res 2023; 315:1181–1186.
Ramachandran V, Phan K. Mohs micrographic surgery versus wide local excision for eyelid melanoma: an analysis of a national database. J Plast Reconstr Aesthet Surg 2022; 75:4410–4415.
Ul Kadir SM, Rani Mitra M, Rashid R, Nuruddin M, Hassan Khan MK, Haider G, et al. clinicopathological analysis and surgical outcome of eyelid malignancies: a study of 332 cases. J Skin Cancer 2022; 2022:4075668.
Han Y, Kong M, Luo Y, Sun B, Wang Z, Zhang H. Clinicopathological features of patients with wide local excision of eyelid malignant neoplasms: a more than five years retrospective study from China. BMC Ophthalmol 2022; 22:436.
Huang YY, Hou T-Y, Yu W-K, Tsai C-C, Kao S-C, Hsu W-M, et al. The clinical feature and treatment outcome of ocular melanoma: a 34-year experience in a tertiary referral center. Cancers (Basel) 2021; 13:5926.
Tas F, Erturk K. Palpebral cutaneous melanomas: a review of 17 cases from a tertiary center. Int J Dermatol 2019; 58:75–79.
Pfeiffer ML, Ozgur OK, Myers JN, Peng A, Ning J, Zafereo ME, et al. Sentinel lymph node biopsy for ocular adnexal melanoma. Acta Ophthalmol 2017; 95:e323–e328.
Pinto V, Zannetti G, Villani R, Tassone D, Cipriani R, Piccin O. Long term cosmetic and functional results of one stage reconstruction for lower eyelid malignant melanoma: a single centre experience of eleven patients. J Maxillofac Oral Surg 2018; 17:625–629.
Rawlani R, Rawlani V, Qureshi HA, Kim JY, Wayne JD. Reducing margins of wide local excision in head and neck melanoma for function and cosmesis: 5-year local recurrence-free survival. J Surg Oncol 2015; 111:795–799.
Elia MD, Lally SE, Hanlon AM, Choi JN, Servat JJ, Shields JA, et al. Periocular melanoma in situ treated with imiquimod. Ophthalmic Plast Reconstr Surg 2016; 32:371–373.
Yin VT, Warneke CL, Merritt HA, Esmaeli B. Number of excisions required to obtain clear surgical margins and prognostic value of AJCC T category for patients with eyelid melanoma. Br J Ophthalmol 2014; 98:1681–1685.
Zollino I, Riberti C, Candiani M, Candotto V, Carinci F. Eyelid reconstruction following excision of cutaneous malignancy. J Craniofac Surg 2014; 25:e13–e17.